- Yuhan Corp reported a parent operating profit of 45.63 billion won for the second quarter.
- Parent sales for the same period reached 556.17 billion won.
- The company’s parent net income amounted to 39.00 billion won in the second quarter.
- Analyst recommendations for Yuhan Corp include 14 “buy” ratings, indicating strong confidence in the company’s performance.
- There are no “hold” ratings, suggesting analysts do not believe the stock should be retained without taking action.
- Three “sell” ratings are identified, showing a minority opinion that the stock might be overvalued or face challenges.
A look at Yuhan Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Yuhan Corp, a company specializing in pharmaceutical products and more, shows a promising long-term outlook based on its Smartkarma Smart Scores analysis. With scores indicating moderate value and dividend strength, alongside solid growth potential, the company demonstrates a strong foundation. Additionally, its high marks for resilience and momentum further bolster confidence in its future performance. These scores collectively paint a picture of a company well-positioned for sustained success in the pharmaceutical industry.
Yuhan Corporation, known for manufacturing and marketing pharmaceutical products, personal care items, and more, has received favorable ratings across key factors crucial for long-term success. The company’s focus on innovation, coupled with its ability to weather challenges and maintain growth momentum, sets the stage for a bright future. Investors may find Yuhan Corp‘s well-balanced Smart Scores indicative of a reliable and potentially rewarding investment opportunity in the healthcare sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
